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Abstract  
Hereditary sensory and autonomic neuropathy type 1 (HSAN1) is a monogenic, 
autosomal dominantly inherited, neurodegenerative disorder resulting in loss of pain and 
temperature sensation in the distal limbs. HSAN1 is caused by point mutations in a single 
allele of serine palmitoyltransferase long chain base 1 (SPTLC1), resulting in production 
of neurotoxic deoxysphingolipids (dSLs).  Oligonucleotide therapeutics (ONTs) can be 
used to downregulate the mutant allele and/or the wild type allele and thus are viable 
treatment strategies.  We investigated the ability of two classes of ONTs, short interfering 
RNAs (siRNAs) and antisense oligonucleotides (ASOs), to downregulate SPTLC1 in an 
in vitro model of HSAN1 derived from the C133W mouse model overexpressing mutant 
hamster SPTLC1. We screened a panel of siRNAs and ASOs targeting mutant hamster 
SPTLC1 and identified four lead compounds.  We demonstrated these compounds’ 
ability to reduce mutant hamster SPLTC1 and/or wild type mouse SPTLC1 mRNA in 
CHO cells and C57BL/6J embryonic mouse primary cortical neurons.  We then showed 
that these compounds downregulate hamster and mouse SPTLC1 mRNA and protein in 
embryonic primary cortical neuron cultures derived from C133W mice.  These 
compounds demonstrate therapeutic potential and should be developed further in vivo.   
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Introduction 
Hereditary sensory and autonomic neuropathy Type 1 (HSAN1) is an autosomal 
dominantly inherited, neurodegenerative disorder with onset in early adulthood 
(McCampbell, Truong et al. 2005).  It is characterized initially by painful hypersensitivity 
to minimal stimuli, which progresses to loss of pain and temperature sensation primarily 
affecting distal limbs (Auer-Grumbach 2008),(Nicholson 2006).  The underlying 
pathology, which correlates well with symptomatology, entails loss of small myelinated 
and unmyelinated sensory nerve fibers and their corresponding dorsal root ganglia 
(Garofalo, Penno et al. 2011).  Denervation of distal limb muscles leads to wasting and 
weakness in some cases (McCampbell, Truong et al. 2005).  In some individuals there is 
compromise of autonomic nerve function as well, although this is not a prominent aspect 
of HSAN1 (Eichler 2018).  
 
The first description of the molecular basis of HSAN1 followed genetic linkage analysis 
in large HSAN1 families in Australia (Nicholson, Dawkins et al. 2001) and identification 
of missense mutations in the gene serine palmitoyltransferase long chain base 1 
(SPTLC1) (Dawkins, Hulme et al. 2001), encoding the protein long chain base 1 (LCB1).  
LCB1 is a subunit of enzyme serine palmitoyltransferase (SPT) (Bejaoui, Wu et al. 
2001).  To date, several disease-associated point mutations in the SPTLC1 gene have 
been identified, including C133W, C133Y, V144D, C133R, A352V, S331F, and S331Y 
(Garofalo, Penno et al. 2011), (Bode, Bourquin et al. 2016), (Suh, Hong et al. 2014).  
11 
 
SPT normally catalyzes the condensation of serine with palmitoyl coA to form 3-keto-
sphinganine; this is the initial, rate-limiting step of ceramide and sphingolipid 
biosynthesis (Hanada 2003).  The disease-causing mutations cluster around the active site 
of SPT and perturb the geometry of the active site (Eichler, Hornemann et al. 2009), 
rendering it more promiscuous and permitting alanine and glycine as well as serine to 
react with palmitoyl coA (Penno, Reilly et al. 2010).  This reaction produces two 
neurotoxic deoxysphingolipids (dSLs), 1-deoxysphinganine (doxSA) and 1-
deoxymethylsphinganine (doxSO), that are thought to be causative agents of disease 
(Penno, Reilly et al. 2010).  Thus the disease-causing mutations represent a toxic gain of 
function.   
 
We believe modulation of SPTLC1 is a potential treatment strategy for HSAN1, with 
allele-specific reduction being the optimal strategy.  Previous studies show that the ratio 
of wild type to mutant SPTLC1 impacts disease severity in the C133W mouse model 
while homozygous knockout mice exhibit embryonic lethality (Eichler, Hornemann et al. 
2009).  Allele-specific silencing would enable downregulation of the toxic allele while 
preserving function of the wild type allele.  Several lines of evidence establish that dSL 
levels influence disease severity (Garofalo, Penno et al. 2011).  So, even reduction of 
both wild type and mutant SPTLC1 may also be beneficial.  This strategy necessitates 
that the degree of silencing of both alleles is high enough to reduce toxic dSLs to below 
the disease-causing threshold but not enough to cause problems due to lack of gene 
expression.  McCampbell et al. previously developed a mouse model overexpressing 
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mutant hamster C133W in a wild type mouse background and accurately recapitulating 
the HSAN1 disease phenotype, including the production of toxic dSLs (McCampbell, 
Truong et al. 2005).  Downregulating SPTLC1 in the C133W model uniquely allows 
investigation of the biological consequences of SPTLC1 modulation by enabling 
differential targeting of mutant and wild type SPTLC1 on the basis of gene sequence 
differences in hamster (mutant) SPTLC1 and mouse (wild type) SPTLC1.    
 
The antisense oligonucleotide (ASO) and short interfering RNA (siRNA) classes of 
oligonucleotide therapeutics have had several recent successes in clinical development.  
Double stranded siRNA therapeutic patisiran, designed by Alnylam to treat hATTR 
(hereditary amyloidogenic transthyretin) Amyloidosis, completed a Phase III trial with a 
promising efficacy and side effect profile (2018).  The FDA also recently approved the 
first Gapmer ASO drug, mipomersen, for homozygous familial hypercholesterolemia 
(Shen and Corey 2017).  Gapmers are single-stranded ASOs with a central DNA “gap,” 
flanked by chemically modified nucleotides (Khvorova and Watts 2017).  ASOs and 
siRNAs have also been shown to be effective in the treatment of central nervous system 
conditions.  For example, nusinersen is a splice-switching ASO that is the first FDA-
approved drug for treatment of Spinal Muscular Atrophy (Shen and Corey 2017). Splice-
switching ASOs are oligonucleotides that bind to pre-mRNAs and disrupt normal 
splicing, leading to an altered set of spliced transcripts (Watts and Corey 2012).  This is 
in contrast to Gapmer ASOs, which function by forming a heteroduplex of DNA and 
RNA by base pairing with the target mRNA and recruiting RNase H to cleave the target 
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(Khvorova and Watts 2017).  The Khvorova lab also previously showed that chemically 
modified siRNAs can ameliorate the Huntington phenotype in a mouse model (Alterman, 
Hall et al. 2015).  
 
Thus, we set out to conduct a proof of concept study investigating the impact of ASOs 
and chemically modified siRNAs downregulating hamster SPTLC1 in an in vitro context.  
We designed, synthesized, and screened a panel of siRNAs and chemically modified 
ASOs and identified compounds that target hamster SPTLC1.  We also identified a 
compound solely targeting mouse SPTLC1.  We showed that these compounds 
demonstrate efficacy in Chinese hamster ovary (CHO-K1) cells, mouse cortical primary 
neurons, or both.  We then utilized an in vitro model for assessing knockdown of 
SPTLC1 by deriving primary embryonic cortical neurons from C133W transgenic mice 
and demonstrated reduction in the appropriate mRNA and protein.  We also evaluated the 
impact of these compounds on dSL levels in this system.  Thus this study describes the 
development and validation of novel ASOs and chemically stabilized siRNAs which 
allow modulation of hamster SPTLC1.  These compounds can be used to evaluate the 
feasibility of oligonucleotide therapeutics for treatment of HSAN1 in the future.   
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Materials and Methods 
Oligonucleotide Synthesis, Deprotection, and Purification 
Oligonucleotide synthesis, deprotection, and purification were conducted as described 
previously (Osborn, Coles et al. 2018).  Oligonucleotides were synthesized on an 
Expedite Applied Biosystems DNA/RNA Synthesizer following standard protocols. Each 
synthesis was done on a 1 µmole scale using cholesterol-conjugated controlled pore glass 
(CPG) solid supports for the sense strand and Unylinker solid support (ChemGenes, 
USA) for the antisense strand.  
Cell culture 
CHO-K1 cells (ATCC, USA) were grown in F12-K medium (ATCC, USA) 
supplemented with 10% fetal bovine serum (FBS; Gibco, USA) and 1% 
penicillin/streptomycin (Invitrogen, USA).  Cells were maintained at 37 °C with 5% CO2, 
and were subcultured 1:4-1:8 every 2-3 days with medium renewal once between 
subcultures.  Cultures were discarded after 15 passages. 
Preparation of primary neurons  
Primary neuron cultures were prepared using a previously described method (Alterman, 
Coles et al. 2017).  Briefly, pregnant females were euthanized by isoflurane overdose and 
uterine horns were dissected out and placed into a petri dish containing DMEM.  
Individual embryos were removed from the uterus and brains of individual embryos were 
dissected out and placed into a petri dish containing Hibernate E (Thermo Fisher, USA).  
15 
 
Cortices were microdissected out and chemically dissociated for 30 minutes using a pre-
warmed solution of DNAse I (Worthington, USA) and papain (Worthington, USA).  The 
dissociation solution was then removed and cortices were resuspended in complete 
NeuralQ medium (Sigma Aldrich, USA) supplemented with 2.5% FBS and mechanically 
disrupted by passing them repeatedly through a glass-blown Pasteur pipette.  Cortical 
neurons were counted and plated at 1 × 105 cells per ml in precoated poly-L-lysine 96 
well-plates.  (BD BIOCOAT, Corning, USA).  
For transgenic primary cortical neuron cultures, heterozygous transgenic C133W mice 
(C57BL/6J) were crossed with wild type C57BL/6J mice to produce a heterogeneous 
pool of heterozygous transgenic mice and wild type mice.  All embryos from each litter 
were used to generate homogenous transgenic cultures, which were pooled and then 
aliquoted.  Thus, the different wells in each experiment should theoretically contain the 
same ratio of transgene/WT SPTLC1.  Primary cortical neurons were harvested from 
FVB/NJ mouse embryos for wild type mouse cultures or embryos from crossing 
transgenic and wild type mice for transgenic cultures at embryonic day 15.5-17.5.  
Genotyping  
Several C133W transgenic lines were developed previously.  Here, animals from the 8E 
line were used.  Animals were genotyped as follows: tail snips were taken at ~28 days of 
age and tissue was processed using the DNeasy blood and tissue extraction kit.  The 
transgene was detected by multiplex PCR amplification DNA using the following 
primers: F, 5′-CGAAAAACCATCCTGCTCTC-3′; R, 5′-
16 
 
GGACAGACGGTTCCAGTGTT-3′ for the transgene, and F, 5′-
GAGGGAGGTGGAAGGAAAGA-3′; R. 5′-GAAGGGTTGTTGCTCTGACC-3′ for the 
mouse ABCD1 gene, a positive control.   
Lipid-mediated delivery of oligonucleotides in cell lines 
 For LNA (Locked Nucleic Acid) Gapmer screen experiments assaying knockdown of 
mRNA, CHO-K1 cells were plated in cell solution (CHO-K1 cells in F12-K medium 
supplemented with 6% FBS) at a density of 10,000 cells per well in 96-well tissue culture 
plates. OptiMEM was used to dilute compounds to 400 nM concentration.  RNAiMax 
(Thermo Fisher, USA) was diluted to 1.2% concentration and an equal volume of the 
solution was added to the compounds.  Cells were treated by adding 50 μl of diluted 
hsiRNA to 50 μl of cell solution, resulting in a final FBS concentration of 3% and final 
compound concentration of 100nM. Cells were incubated for 72 hours before harvesting 
for mRNA quantification.   
Passive delivery of oligonucleotides in cell lines 
For mRNA dose response experiments in CHO-K1 cells, CHO-K1 cells were plated in 
F12-K medium supplemented with 6% FBS at a density of 10,000 cells per well in 96-
well tissue culture plates. OptiMEM was used to dilute compounds to 6 μM 
concentration.  Cells were treated by adding 50 μL of diluted hsiRNA to 50 μL of cell 
solution, resulting in a final FBS concentration of 3% and final compound concentration 
of 3 μM.  Compounds were serially diluted in Opti-MEM two-fold within a range of 3 
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μM to 0 nM, with cells incubated for 1 week.  Cells were fed with fresh media without 
compounds on day 4-5 after treatment.   
Treatment of primary neurons with oligonucleotides 
mRNA knockdown dose response experiments in mouse primary cortical neurons were 
carried out as described above with all concentrations as two-fold serial dilutions from 
1.5 μM except the 1 μM concentration.  Protein knockdown experiments in primary 
cortical neurons were carried out using the same protocol, but cells were treated with 
only 1.5 μM compounds.  For dSL knockdown experiments in primary cortical neurons, 
neurons were plated at 1.5E6 per well in 1.5 mL, in 6-well plates pre-coated in poly-L-
lysine.  In a similar protocol to the above experiments, cells were fed with 1.5 mL media 
containing antimitotics one day after preparation of cortical cultures, then treated with 
compounds at a concentration of 1.5 μM for 1 week.  Cells were disrupted by pipeting 
with cold PBS and then pelleted.  Cell pellets were processed for dSL quantitation.   
mRNA quantification 
mRNA was quantified using the QuantiGene 2.0 Assay (Affymetrix; #QS0011) as 
previously described (Alterman, Coles et al. 2017).  Briefly, cells from triplicate wells 
were lysed in lysis buffer and proteinase K at 55 oC for thirty minutes and each was 
mixed thoroughly.  Capture plates were prepared by plating 20 μL probe set per well, the 
appropriate amount of cell lysate as described below, and a volume of diluted lysis 
mixture such that the total volume of the sample was 100 μL.   
18 
 
For experiments using transgenic neurons, 20 μL of lysate were used to quantitate 
hamster SPTLC1, 40 μL for mouse SPTLC1, 20 μL for mouse HPRT, 10 μL for mouse 
PPIB.  The amounts of lysate used for quantitation were determined by investigating 
assay linearity (see Supplemental figure S1).  Probe sets used for assays in transgenic 
neurons were species-specific.   
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 Figure S1. Development and Validation of Assay for Selective 
Detection of Hamster and Mouse SPTLC1 mRNA. 
CHO cells, wt mouse primary neuron and transgenic mouse primary neuron 
(expressing hamster C133W SPTLC1) lysates were evaluated for SPTLC1 
mRNA expression using species-selective QuantiGene Assays, (A) mouse 
specific probe set (B) hamster specific probe set. N=2, SD.  Signal to Noise 
was calculated by dividing luminescence of indicated mRNA to background 
luminescence using either mouse or hamster SPTLC1 probe set.   
20 
 
 
Dual-Glo Assay for hsiRNA compound screen 
 Hamster SPTLC1 hsiRNA target sequences were concatenated and a donor oligo was 
synthesized (IDT Technologies, USA) (Fig. S2).  Donor DNA was cloned into 
psiCHECK2 vector in the 3’UTR of the Renilla luciferase gene using restriction sites for 
AsiS-I and Not-I.  HeLa cells plated at 80% confluency were transfected for 6 hours with 
24 μg DNA using lipofectamine 2000 transfection reagent diluted in serum-free 
OptiMEM media, then media was changed to DMEM media supplemented with 10% 
FBS and 1% penicillin-streptomycin.  Cells were trypsinized the following day and 
plated in a 96-well plate at a density of 10,000 cells/50 μL.  Cells were treated with 50 μL 
of compounds diluted to 1.5 μM for 72 hours.  Dual Glo reagents were added as 
described in the Dual Glo Assay protocol (Promega, USA) and Renilla and Firefly 
luminescence were read (Veritas, Promega, USA).  Data were processed by combining 
the results of two identical experiments of cells treated with each compound in triplicate.  
For each compound, each of six values of Renilla luciferase was divided by its 
corresponding Firefly luciferase value.  
21 
 
 
 
 
 
  
Figure S2. psiCHECK2 donor oligonucleotide contains hsiRNA target sequences  
An oligonucleotide containing hsiRNA target sequences was cloned into the psiCHECK2 plasmid in the 3’UTR 
of the Renilla luciferase gene. Target locations of oligonucleotides are shown.  This plasmid was used in 
screening experiments to determine functional hsiRNAs.   
22 
 
Western blot 
Westerns were performed using a previously described method (Wright, Huang et 
al. 2010).  Briefly, cell lysates were prepared by lysing cell cultures from a 96 
well plate in RIPA buffer and combining material from 6 wells (~600,000 cells per 
sample).  Fifteen μg of total protein from lysates was loaded onto 12% Tris-
Glycine gels (Novex, USA) and separated by gel electrophoresis at 120V for 1.5 
hours.  Proteins were transferred to nitrocellulose membranes and blots were 
blocked at room temperature for 1-2 hours.  Membranes were incubated overnight 
at 4 oC with mouse anti-LCB1 (BD Pharmingen, USA), diluted 1:500 and the 
loading control goat anti-beta actin (Abcam, USA) diluted 1:3000.  Mouse and 
hamster LCB1 protein was normalized to beta actin protein and each sample was 
compared to untreated within each experiment.   
Quantitation of sphingolipids 
Sphingolipid content of transgenic embryonic primary cortical neurons was quantitated 
by LCMS using previously described techniques (Penno, Reilly et al. 2010).   
Statistical Analysis  
Data were analyzed using GraphPad Prism version 7.04.  The log(inhibitor) versus 
response-variable slope (four parameters) method was used to fit concentration-
dependent IC50 curves and calculate IC50 values.  For analysis of screening data and 
protein knockdown data, normality of data was assessed with the D’Agostino-Pearson 
test.  Based on the results (indicating lack of normality and thus the need for non-
23 
 
parametric statistics), the results of the hsiRNA and ASO screens was evaluated by the 
Kruskal-Wallis test with Dunn’s multiple comparisons test for post-hoc analysis.  Other 
analyses indicated normally distributed data and parametric tests were conducted.  
Protein knockdown for both mouse and hamster knockdown was assessed separately 
using a One-Way ANOVA, followed by Dunnett’s Multiple Comparisons test to assess 
group differences from UNT values.  Branched DNA assays for mRNA knockdown of 
hamster and/or mouse SPTLC1 mRNA were evaluated using Two-Way ANOVA.   
 
Results  
Design of siRNAs and ASOs for downregulation of hamster and/or mouse SPTLC1. 
HSAN1 is a monogenic disorder with a toxic gain-of-function mechanism (Penno, Reilly 
et al. 2010) and thus an ideal candidate for gene silencing strategies including RNAi-
based approaches to gene knockdown.  McCampbell et al. previously developed and 
characterized a mouse model of HSAN1 overexpressing the C133W mutant hamster 
(hamster) SPTLC1 transgene in 2005.  In this study, we sought to identify siRNAs and 
ASOs targeting hamster and mouse SPTLC1 to evaluate efficacy and toxicity of these 
compounds in the context of this model.  To this end, we designed a panel of 39 hsiRNAs 
and 16 LNA Gapmers targeting hamster SPTLC1.  As the mutant transgene does not 
contain the 3’UTR, we limited the sequence space to the ORF only.  We identified 
sequences able to target both mouse SPTLC1 and hamster SPTLC1 through analysis of 
regions with shared mouse/hamster homology, as well as sequences that predicted to 
target hamster SPTLC1 or mouse SPTLC1 only (Fig. 1).  hsiRNA sequences were 
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developed based on standard siRNA design criteria such as preferring oligonucleotides 
that have mid-range GC content, absence of miRNA seed sequences, absence of G 
stretches, and absence of toxic motifs, among other criteria (Birmingham, Anderson et al. 
2007).  
25 
 
 
 
 
 
 
  
Figure 1. Sequence alignment of hamster, mouse, and human SPTLC1 indicates hsiRNA reagents’ 
target sequences and ability to target different species.    
Sequences of hamster, mouse, and human SPTLC1 in relevant regions are shown. All reagents were designed 
to target hamster SPTLC1 except hsiRNA_1139 (shown in purple), which is designed to target mouse SPTLC1 
but does not target hamster or human SPTLC1. Red = targeted, Black = non-targeted, Blue = mismatch.  
26 
 
The asymmetric siRNA scaffold extensively characterized in Dr. Khvorova’s lab was 
used for the screening.  The siRNAs have an antisense strand of 20 bases and a sense 
strand of 15 bases, resulting in the formation of the short duplex region in addition to the 
fully phosphorothioated tail.  An alternating 2ʹ–O–methyl, 2ʹ–fluoro pattern, with a 
chemically monophosphorylated, 2ʹ–O–methyl–modified uridine (U) at position 1, in 
combination with terminal phosphorothioated backbone modifications was used to 
protect from nuclease degradation (Fig. 2a).   When conjugated to cholesterol, these 
compounds efficiently internalize in vitro in all cell types tested without formulation 
(data not shown) and can silence genes in mice (Alterman, Hall et al. 2015).  The exact 
sequences, chemical configurations, and efficacy of compounds used for screening and 
initial characterization are shown in Table 1.   
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Figure 2. Structure and chemical composition of hsiRNAs and ASOs  
(A) hsiRNAs are hydrophobically modified through conjugation of cholesterol 
and addition of phosphorothioate linkages.  2`-F and 2`-OMe modifications 
confer nuclease resistance.  Two generations of chemical modification 
patterns were used.  (B) LNA Gapmers (ASOs) are fully phosphorothioated 
and contain LNA modifications in regions flanking a central DNA gap 
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Table 1 Detailed sequence, chemical modification patterns, and efficacy of hsiRNAs targeting hamster SPTLC1 
      
 
  Strand Modifications  
  
Gene Position Sense Strand Antisense Strand C. griseus M. musculus 
 
 
 
H. 
sapiens 
IC50 Passive 
Uptake (nM), 
CHO cells 
hsiRNA_183_P0 183 mA.mC.mU.G.A.mU.mU.G.A.mA.G.A.mG#mU#mA.tegChol PmU.A.fC.U.fC.U.fU.fC.A.A.fU.fC.A.G#fU#fU#C#fC#fU#C yes yes yes N/A 
hsiRNA_186_P0 186 mG.mA.mU.mU.G.A.mA.G.A.mG.mU.G.G#mC#mA.tegChol PmU.G.fC.fC.A.fC.U.fC.U.fU.fC.A.A.fU#fC#A#G#fU#fU#C yes yes yes N/A 
hsiRNA_187_P0 187 mA.mU.mU.G.A.mA.G.A.mG.mU.G.G.mC#mA#mA.tegChol PmU.fU.G.fC.fC.A.fC.U.fC.U.fU.fC.A.A#fU#fC#A#G#fU#U yes yes yes N/A 
hsiRNA_240_P0 240 mU.mG.mC.mU.mC.mU.mC.A.A.mC.mU.A.mC#mA#mA.tegChol PmU.fU.G.fU.A.G.fU.fU.G.A.mG.A.G.fC#A#G#mG#A#fU#G yes yes yes N/A 
hsiRNA_241_P0 241 mG.mC.mU.mC.mU.mC.A.A.mC.mU.A.mC.A#mA#mA.tegChol PmU.fU.fU.G.fU.A.G.fU.fU.G.A.mG.A.G#fC#A#G#mG#A#U yes yes yes N/A 
hsiRNA_242_P0 242 mC.mU.mC.mU.mC.A.A.mC.mU.A.mC.A.A#mC#mA.tegChol PmU.G.fU.fU.G.fU.A.G.fU.fU.G.A.mG.A#G#fC#A#G#mG#A yes yes yes N/A 
hsiRNA_244_P0 244 mC.mU.mC.A.A.mC.mU.A.mC.A.A.mC.A#mU#mA.tegChol PmU.A.fU.G.fU.fU.G.fU.A.G.fU.fU.G.A#mG#A#G#fC#A#G yes yes yes N/A 
hsiRNA_245_P0 245 mU.mC.A.A.mC.mU.A.mC.A.A.mC.A.mU#mC#mA.tegChol PmU.G.A.fU.G.fU.fU.G.fU.A.G.fU.fU.G#A#mG#A#G#fC#A yes yes yes N/A 
hsiRNA_246_P0 246 mC.mA.A.mC.mU.A.mC.A.A.mC.A.mU.mC#mG#mA.tegChol PmU.fC.G.A.fU.G.fU.fU.G.fU.A.G.fU.fU#G#A#mG#A#G#C yes yes yes N/A 
hsiRNA_249_P0 249 mC.mU.A.mC.A.A.mC.A.mU.mC.G.mU.mU#mU#mA.tegChol PmU.A.A.mA.fC.G.A.fU.G.fU.fU.G.fU.A#G#fU#fU#G#A#G yes  yes N/A 
hsiRNA_370_P0 370 mC.mU.A.G.mC.A.mU.mC.mU.mC.mU.A.A#mA#mA.tegChol PmU.fU.U.fU.A.G.mA.G.A.fU.G.fC.fU.A#G#mA#G#fC#fU#G yes   185 
hsiRNA_373_P0 373 mG.mC.A.mU.mC.mU.mC.mU.A.A.mA.G.A#mA#mA.tegChol PmU.fU.U.fC.U.fU.fU.A.G.mA.G.A.fU.G#fC#fU#A#G#mA#G yes  yes N/A 
hsiRNA_374_P0 374 mC.mA.mU.mC.mU.mC.mU.A.A.mA.G.A.mA#mG#mA.tegChol PmU.fC.U.fU.C.fU.U.fU.A.G.mA.G.A.fU#G#fC#fU#A#G#A yes  yes 448 
hsiRNA_376_P0 376 mU.mC.mU.mC.mU.A.A.mA.G.A.mA.G.mU#mA#mA.tegChol PmU.fU.A.fC.U.fU.fC.U.fU.fU.A.G.mA.G#A#fU#G#fC#fU#A yes  yes N/A 
hsiRNA_377_P0 377 mC.mU.mC.mU.A.A.mA.G.A.mA.G.mU.A#mU#mA.tegChol PmU.A.fU.A.fC.U.fU.fC.U.fU.fU.A.G.mA#G#A#fU#G#fC#U yes  yes N/A 
hsiRNA_378_P0 
hsiRNA_379_P0 
378 mU.mC.mU.A.A.mA.G.A.mA.G.mU.A.mU#mG#mA.tegChol 
mC.mU.A.A.mA.G.A.mA.G.mU.A.mU.G#mG#mA.tegChol 
PmU.fC.A.fU.A.fC.fU.U.fC.fU.U.fU.A.G#mA#G#A#fU#G#C 
PmU.fC.fC.A.fU.A.fC.U.fU.C.fU.U.fU.A#G#mA#G#A#fU#G 
yes 
yes  
yes 
yes 
N/A 
N/A 379 
hsiRNA_409_P0 409 mC.mC.mU.mC.G.A.mG.G.A.mU.mU.mU.mU#mA#mA.tegChol PmU.fU.A.A.mA.A.fU.fC.C.fU.fC.G.A.mG#G#fU#fC#fC#A#C yes   N/A 
hsiRNA_421_P0 421 mU.mA.mU.G.G.mC.A.mC.A.mU.mU.mU.G#mA#mA.tegChol PmU.fU.fC.A.A.mA.fU.G.fU.G.fC.fC.A.fU#A#A#mA#A#fU#C yes yes yes N/A 
hsiRNA_422_P0 422 mA.mU.G.G.mC.A.mC.A.mU.mU.mU.G.A#mU#mA.tegChol PmU.A.fU.fC.A.A.mA.fU.G.fU.G.fC.fC.A#fU#A#A#mA#A#U yes yes yes N/A 
hsiRNA_424_P0 424 mG.mG.mC.A.mC.A.mU.mU.mU.G.A.mU.G#mU#mA.tegChol PmU.A.fC.A.fU.fC.A.A.mA.fU.G.fU.G.fC#fC#A#fU#A#A#A yes yes yes N/A 
hsiRNA_591_P0 591 mC.mC.A.G.mA.A.A.mG.G.mC.mU.mU.A#mC#mA.tegChol PmU.G.fU.A.A.mG.fC.C.fU.fU.U.fC.fU.G#G#mA#fU#A#G#C yes   N/A 
hsiRNA_630_P0 630 mG.mU.mU.mC.A.A.mG.mC.A.mC.A.A.mU#mG#mA.tegChol PmU.fC.A.fU.fU.G.fU.G.fC.fU.fU.G.A.mA#fC#A#A#fC#fU#U yes   N/A 
hsiRNA_635_P0 635 mA.mG.mC.A.mC.A.A.mU.G.A.mU.G.mU#mA#mA.tegChol PmU.fU.A.fC.A.fU.fC.A.fU.fU.G.fU.G.fC#fU#fU#G#A#mA#C yes   N/A 
hsiRNA_666_P0 666 mG.mC.mU.G.A.mA.A.G.mA.A.mC.A.A#mG#mA.tegChol PmU.fC.U.fU.G.fU.fU.C.fU.fU.U.fC.A.G#fC#A#G#fU#fC#G yes   N/A 
hsiRNA_669_P0 669 mG.mA.mA.A.G.mA.A.mC.A.A.mG.A.G#mA#mA.tegChol PmU.fU.C.fU.fC.U.fU.G.fU.fU.C.fU.fU.U#fC#A#G#fC#A#G yes   749 
hsiRNA_741_P0 741 mA.mG.mG.A.mU.mU.G.mU.A.mU.A.mU.G#mA#mA.tegChol PmU.fU.fC.A.fU.A.fU.A.fC.A.A.fU.fC.C#fU#fU#fC#fC#A#C yes  yes 780 
hsiRNA_742_P0 742 mG.mG.mA.mU.mU.G.mU.A.mU.A.mU.G.A#mA#mA.tegChol PmU.fU.U.fC.A.fU.A.fU.A.fC.A.A.fU.fC#fC#U#fU#fC#fC#A yes  yes N/A 
hsiRNA_748_P0 748 mU.mA.mU.A.mU.G.A.mA.mC.A.mC.mU.G#mG#mA.tegChol PmU.fC.fC.A.G.fU.G.fU.fU.fC.A.fU.A.fU#A#fC#A#A#fU#C yes   N/A 
hsiRNA_794_P0 794 mU.mA.A.mA.G.mU.A.mC.A.A.mA.mU.A#mU#mA.tegChol PmU.A.fU.A.fU.U.fU.G.fU.A.fC.U.fU.fU#A#A#fC#fU#fU#A yes   N/A 
hsiRNA_795_P0 795 mA.mA.mA.G.mU.A.mC.A.A.mA.mU.A.mU#mA#mA.tegChol PmU.fU.A.fU.A.fU.U.fU.G.fU.A.fC.U.fU#fU#A#A#fC#fU#U yes   N/A 
hsiRNA_799_P0 799 mU.mA.mC.A.A.mA.mU.A.mU.A.A.mA.G#mC#mA.tegChol PmU.G.fC.U.fU.fU.A.fU.A.fU.U.fU.G.fU#A#fC#fU#fU#fU#A yes   N/A 
hsiRNA_800_P0 800 mA.mC.A.A.mA.mU.A.mU.A.A.mA.G.mC#mA#mA.tegChol PmU.fU.G.fC.fU.U.fU.A.fU.A.fU.fU.fU.G#fU#A#fC#fU#fU#U yes   N/A 
hsiRNA_801_P0 801 mC.mA.A.mA.mU.A.mU.A.A.mA.G.mC.A#mA#mA.tegChol PmU.fU.fU.G.fC.U.fU.fU.A.fU.A.fU.U.fU#G#fU#A#fC#fU#U yes   N/A 
hsiRNA_803_P0 803 mA.mA.mU.A.mU.A.A.mA.G.mC.A.A.mG#mA#mA.tegChol PmU.fU.fC.U.fU.G.fC.U.fU.fU.A.fU.A.fU#fU#fU#G#fU#A#C yes yes  N/A 
hsiRNA_825_P0 825 mG.mG.mA.G.G.mA.A.A.mG.mC.mC.mU.mU#mU#mA.tegChol PmU.A.A.mA.G.G.fC.fU.U.fU.fC.fC.U.fC#fC#A#G#mA#A#A yes  yes N/A 
hsiRNA_918_P0 918 mU.mG.mC.mC.A.A.mC.A.mU.G.G.mA.G#mA#mA.tegChol PmU.fU.fC.U.fC.fC.A.fU.G.fU.fU.G.G.fC#A#fC#fU#G#A#U yes  yes N/A 
hsiRNA_1125_P0 1125 mC.mC.A.mU.A.A.mA.mU.mC.mU.mC.mU.A#mC#mA.tegChol PmU.G.fU.A.G.mA.G.A.fU.fU.fU.A.fU.G#G#mA#fU#G#fU#G yes   1074 
hsiRNA_1138_P0 1138 mC.mA.A.mG.G.mC.A.mU.mU.mU.mC.mU.G#mG#mA.tegChol PmU.fC.fC.A.G.mA.A.A.fU.G.fC.fC.fU.fU#G#fU#A#G#mA#G yes  yes 177 
Detailed sequence, chemical modification patterns, and efficacy of hsiRNAs.  Chemical modifications are designated as follows.  “.” – phosphodiester bond, “#” –phosphorothioate bond, “m” – 2’-O-Methyl, “f” – 2’-Fluoro, no prefix – ribonucleotide, “P” 
– 5’ Phosphate, “tegChol” – tetraethylene glycol (teg)-cholesterol.  IC50 calculated as described in Materials and Methods.  N/A, Not Assessed 
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Additionally, sixteen LNA Gapmer ASO compounds were designed by Exiqon (USA) 
using a proprietary algorithm.  The ASO scaffold contains a fully phosphorothioated 
backbone, a central gap of DNA nucleotides, typically flanked by 2-4 LNA (Locked 
Nucleic Acid) modified nucleotides in varied positions (Fig. 2b).  The exact sequences 
and efficacy of compounds used for screening and initial characterization are shown in 
Table 2.    
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Table 2 Detailed sequence, chemical modification patterns, and efficacy of ASOs targeting hamster SPTLC1 
 
 
 
 
 
 
  
    Strand Modifications      
Gene Position  Sense Strand 
C. 
griseus 
M. 
musculus 
 
 
 
H. 
sapiens 
IC50 Passive 
Uptake (nM), 
CHO cells 
 
ASO_414 414 T*G*T*G*C*C*A*T*A*A*A*A*T*C*C*T  yes  
 
yes 156 
ASO_419 419 T*C*A*A*A*T*G*T*G*C*C*A*T*A*A*A  yes  yes N/A 
ASO_1153 1153 C*C*C*A*C*C*A*C*T*T*T*T*A*A  yes yes yes N/A 
ASO_1158 1158 G*G*A*C*T*C*C*C*C*C*A*C*C*A*C*T  yes  yes N/A 
ASO_239 239 T*G*T*A*G*T*T*G*A*G*A*G*C*A*G  yes yes yes N/A 
ASO_317 317 A*G*A*A*A*A*T*T*A*A*A*G*G*A*G*G  yes   209 
ASO_1141 1141 T*T*A*A*A*C*C*A*G*A*A*A*T*G*C*C  yes   N/A 
ASO_415 415 T*G*T*G*C*C*A*T*A*A*A*A*T*C*C  yes  yes N/A 
ASO_138 138 A*C*G*C*T*C*T*T*G*C*A*A*T*T*T*G  yes   101 
ASO_813 813 T*C*C*A*G*A*A*A*G*A*T*T*C*T*T  yes   N/A 
ASO_258 258 T*G*G*A*G*G*C*C*C*G*G*A*A*A*C*G        yes   N/A 
ASO_489 489 A*C*G*A*G*T*A*A*A*T*G*A*T*G  yes yes  161 
ASO_689 689 C*T*C*G*G*A*T*T*C*T*T*T*T*G*A*T  yes   155 
ASO_214 214 T*C*G*A*G*A*C*A*G*G*A*G*G*G*A*C  yes   449 
ASO_1286 1286 A*A*G*T*A*G*C*G*C*G*C*C*T*G*A*G  yes  yes 3166 
ASO_1289 1289 T*C*C*A*A*G*T*A*G*C*G*C*G*C*C*T yes  yes 146 
Detailed sequence, chemical modification patterns, and efficacy of ASOs.  Sequences fully phosphorothioated, Exact locations of LNA modifications 
unknown, proprietary to Exiqon.  IC50 calculated as described in Materials and Methods.  N/A, Not Assessed 
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Screen to identify potent siRNAs and ASOs for silencing SPTCL1  
An initial screen of 39 hsiRNAs was conducted by dual luciferase assay (Promega, 
USA).  A psiCHECK2 plasmid expressing Firefly luciferase and containing all hsiRNA 
target sequences cloned into the 3’UTR of the Renilla luciferase was pretransfected into 
HeLa cells.  hsiRNAs targeting hamster SPTLC1 were then passively transfected into 
HeLa cells at a concentration of 1.5 μM.  Using this experimental design, efficacy of 
hsiRNAs can be quantified by comparing the ratios of Renilla/Firefly luciferase of each 
hsiRNA to the ratio of Renilla/Firefly luciferase of untreated cells.  Two identical 
screening experiments were performed, each with triplicate wells.  One screen exhibited a 
hit rate of 25.6% while the other had a hit rate of 15.4%, for compounds silencing the 
gene to less than 50% of untreated controls.  Of these lead compounds, four were 
common among the two screens.  Additionally, three compounds in the first screen and 
two compounds in the second screen silenced their SPTLC1 targets by ~70% or more 
(Fig. S3).  Statistical analysis of data from both screens together indicated that seven 
compounds were able to significantly downregulate their targets as determined by 
reduction in relative bioluminescence (Renilla/Firefly luminescence) (Fig. 3a).  
Additionally, several compounds exhibited toxicity as indicated by low firefly luciferase 
expression (data not shown).  The two lead compounds chosen were hsiRNA_374 and 
hsiRNA_1138, which averaged 77.9% and 76.8% knockdown, respectively.  
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Figure S3. hsiRNA screen results reveal four common lead compounds  
Two identical hsiRNA screens were conducted by transfection of HeLa cells with psiCHECK2 plasmid 
containing hsiRNA target sequences cloned into 3’UTR of Renilla luciferase gene. Cells were then treated with 
compounds at 1.5 μM concentration for 72 hours, then Renilla and firefly luciferase luminescence were 
detected. Renilla/firefly luciferase expression was expressed as a percent of untreated cells and lead 
compounds were identified as compounds a reduction in Renilla/firefly luminescence as compared to untreated 
of more than 50% (n=3 per experiment).  Four common lead compounds were identified. *, compounds 
reduced Renilla/firefly luminescence to less than 30% in both screens.   
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Similarly, 16 LNAs were screened by treating CHO cells with compounds at a 
concentration of 100 nM for 72 hours.  Compounds were delivered by lipid transfection 
and their efficacy assessed by branched DNA Assay (Quantigene, Affymetrix) 15 out of 
16 of the compounds silenced hamster by more than ~70%, with nine compounds 
silencing by more than 90%.    However, three of these compounds exhibited toxicity as 
indicated by reduced expression of MAP4K4, the housekeeping gene, relative to 
untreated controls (Fig. 3b,c).  Compounds ASO_414, ASO_489, and ASO_1289 were 
the top hits, with efficacies of 92.3, 95.6, and 97.3%, respectively (Fig. 3d).  In 
subsequent experiments (data not shown), ASO_1289 was shown to be ineffective at 
silencing SPTLC1, and ASO_414 and ASO_489   were identified as the top leads.   
 
Lead ASOs and hsiRNAs efficiently and potently knock down hamster SPTLC1 and 
vary in ability to knock down mouse SPTLC1 
The two lead hsiRNA compounds, hsiRNA_1138 and hsiRNA_374, as well as the lead 
two LNA Gapmer compounds were further characterized by conducting dose response 
assays in CHO-K1 cells to evaluate the compounds’ ability to target endogenous hamster 
SPTLC1.  Compounds were passively transfected into cells at concentrations varying 
from 50 nM to 3 μM (Fig. 4a,b).  The two hsiRNA lead compounds appeared to have 
similar efficacies, with hsiRNA_1138 having an IC50 of 359 nM, compared to 
hsiRNA_374, which had an IC50 of 448 nM.  The two lead ASO compounds, ASO_414 
and ASO_489, were equally potent with an IC50 of 155 nM, while ASO_414 appeared 
slightly more efficacious than ASO_489 (Fig. 4a, b).   
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Figure 4. Validation of hsiRNA and ASO Lead Compounds for Silencing 
of Hamster SPTLC1 mRNA in CHO cells.   
CHO cells were treated with different concentrations (passive transfection) 
of hsiRNAs (A) or ASOs (B)  Compound potency was evaluated at 72 hours 
post treatment using QuantiGene Assay. N=3, SD, NTC- Non Targeting 
Control, UNT- Untreated Cells. 
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We also evaluated these compounds’ ability to target mouse SPTLC1, again by passive 
transfection at concentrations varying from 50 nM to 3 μM, but this time in mouse 
primary cortical neurons.  Both hsiRNA_1138 (Fig. 5a) and hsiRNA_374 (data not 
shown) did not have the ability to target mouse SPTLC1.  In order to complete our 
catalogue of compounds, we developed and synthesized a panel of hsiRNA compounds 
targeting mouse SPTLC1 only, by using the mouse –targeting sequences corresponding to 
the position of the top hamster-targeting sequences.  We evaluated these compounds by 
branched DNA assay and identified hsiRNA-1143 as a hit compound with the ability to 
robustly target mouse SPTLC1.  ASO_489 was able to robustly target mouse SPTLC1 
while ASO_414 silenced mouse SPTLC1 but displayed low potency and appeared to 
have lower efficacy (Fig. 5b).  A summary of sequences, chemical modifications, and 
homology for each lead compound is shown in Table 3.   
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Figure 5. Validation of hsiRNA and ASO Lead Compounds for Silencing 
of Mouse SPTLC1 mRNA in Mouse Primary Cortical Neurons.   
Mouse primary neurons were treated with different concentrations (passive 
transfection) of hsiRNAs (A) or ASOs (B).  Compound potency was 
evaluated at 72 hours post treatment using QuantiGene Assay. N=3, SD, 
NTC- Non Targeting Control, UNT- Untreated Cells. Compounds 
hsiRNA_1138 and ASO_414 have mismatches with mouse SPTLC1 mRNA 
and thus are inactive. 
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Table 3 Detailed sequence, chemical modification patterns of lead hsiRNAs and ASOs targeting SPTLC1 
 
  Strand Modifications  
 
Gene Position Sense Strand Antisense Strand C. griseus M. musculus 
 
 
 
H. 
sapiens 
hsiRNA_374_P1 374 fC.mA.fU.mC.fU.mC.fU.mA.fA.mA.fG.mA.fA#mG#fA.tegChol PmU.fC.mU.fU.mC.fU.mU.fU.mA.fG.mA.fG.mA.fU#mG#fC#mU#fA#mG#fA yes  yes 
hsiRNA_1138_P1 1138 fC.mA.fA.mG.fG.mC.fA.mU.fU.mU.fC.mU.fG#mG#fA.tegChol PmU.fC.mC.fA.mG.fA.mA.fA.mU.fG.mC.fC.mU.fU#mG#fU#mA#fG#mA#fG yes  yes 
hsiRNA_1143_P1 1143 fC.mA.fA.mG.fG.mU.fG.mU.fU.mU.fC.mG.fG#mG#fA.tegChol PmU.fC.mC.fC.mG.fA.mA.fA.mC.fA.mC.fC.mU.fU#mG#fU#mA#fG#mA#fG  yes  
 
ASO_414 414 T*G*T*G*C*C*A*T*A*A*A*A*T*C*C*T 
 
yes  
 
yes 
ASO_489 489 A*C*G*A*G*T*A*A*A*T*G*A*T*G  yes yes  161 
Detailed sequence, chemical modification patterns, and efficacy of hsiRNAs.  Chemical modifications are designated as follows.  “.” – phosphodiester bond, “#” –phosphorothioate bond, “m” – 2’-O-Methyl, “f” – 2’-Fluoro, no 
prefix – ribonucleotide, “P” – 5’ Phosphate, “tegChol” – tetraethylene glycol (teg)-cholesterol.  Exact locations of LNA modifications unknown, proprietary to Exiqon.  IC50 calculated as described in Materials and Methods.  
N/A, Not Assessed 
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Lead ASOs and hsiRNAs potently and differentially knock down hamster SPTLC1 
and mouse SPTLC1 mRNA in an in vitro model of HSAN1 
After we established the lead compounds’ differential ability to silence mutant hamster vs 
wild type mouse SPTLC1 when only one species of transcript is present, our next goal 
was to test this in an in vitro model system of HSAN1, which expresses both hamster and 
mouse SPTLC1.  We did this by culturing primary embryonic cortical neurons from 
pregnant wild type females that were crossed with transgenic males.  These cultures had 
sufficient expression of both mutant hamster SPTLC1 and wild type mouse SPLTC1 to 
be able to detect knockdown by the lead compounds (data not shown).  We developed a 
species-specific assay to detect differential expression and knockdown of both transcripts 
using the branched DNA assay.  We then investigated whether the lead compounds 
induced species selective dose-dependent inhibition of transcript levels in these cultures.  
Compounds were administered by passive delivery at a range of concentrations, from 50 
nM to 3 μM.  Among the hsiRNA compounds, hsiRNA_1138 shows selective reduction 
of hamster SPTLC1 (Fig. 6a), while hsiRNA_1143 (Fig. 6b) shows selective reduction of 
mouse SPTLC1.  These hsiRNAs are potent, with IC50s in the 100-300 nM range.  
Among the ASOs, both ASO_414 and ASO_489 downregulate both hamster and mouse 
SPLTC1.  ASO_414 , however, shows greater ability to target hamster SPTLC1 than 
mouse SPTLC1, as evidenced by a lower IC50.  The exact IC50 for ASO_414 as 
determined from best fit nonlinear regression is not reliable as this compound is highly 
effective throughout the range of concentrations tested, but we can conclude it is less than 
50 nM.   
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  Figure 6. Selective Silencing of Hamster and Mouse SPTLC1 mRNA in 
C133W Transgenic Primary Neurons. 
C133W neurons were treated with hsiRNAs and ASOs at a range of 
concentrations from 1.5 μM to 50 nM. Level of Mouse (A) and Hamster (B) 
SPTLC1 mRNA determined at 1 week with Quantigene assay, shown with 
respect to [μM] in bar graphs and log[M] in linear regression curves.  N=3, 
SD, NTC- Non Targeting Control, UNT- Untreated Cells.  IC50 values are 
shown.   
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Lead ASOs and hsiRNAs potently and differentially knock down hamster LCB1 
and mouse LCB1 protein in an in vitro model of HSAN1 
Next, we investigated whether reduction of LCB1 protein mirrored reduction of SPTLC1 
mRNA and whether the knockdown remained species-specific based on the compound 
used.  We treated primary cortical neurons from transgenic animals for 1 week with the 
lead compounds at a concentration of 1.5 μM.  We found that hsiRNA_1138, ASO_414, 
and ASO_489, all showed significant reduction of hamster LCB1 levels, while ASO_414, 
ASO_489, and the mouse-selective hsiRNA_1143  all showed a trend towards reduction 
in mouse LCB1 protein levels that was not significant (Fig. 7a, b).  ASO_414 showed the 
most potent silencing of hamster protein, knocking it down by 85%, while hsiRNA_1143 
was the most potent reagent reducing mouse LCB1 protein, silencing it by ~50%.   
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Figure 7. Selective Silencing of Hamster and Mouse LCB1 Protein in 
C133W Transgenic Primary Neurons. 
C133W neurons were treated with hsiRNAs and ASOs at 1.5 μM 
concentration. (A) Level of hamster and mouse LCB1 protein determined at 
1 week by western blot and quantified by densitometry (B). N=5, SD, NTC- 
Non Targeting Control, UNT- Untreated Cells. *, P ≤ 0.05  
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Lead ASOs and hsiRNAs do not impact dSL production in an in vitro model of 
HSAN1 
In addition to demonstrating potent silencing of SPTLC1 mRNA and protein, we also 
tested the ability of the lead compounds to reduce production of dSLs, which are thought 
to be the causative agent of disease in HSAN1.  We cultured transgenic primary neurons 
and wild type primary neurons and compared their sphingolipid profiles (Fig. 8a).  We 
found that dSLs are indeed expressed in such cultures and they are produced at levels that 
allow detection of knockdown should it occur.  Specifically, doxSO and doxSA are 
present in transgenic cultures at average levels of 0.046 and 0.026 pmol/ug, respectively, 
when normalized to the internal standard d7SO.  These species were not detectable in 
wild type cultures.   
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Figure 8. Primary Cortical Neuron Cultures Produce dSLs 
(A) Sphingolipid profiles of transgenic and wild type primary cortical neurons 
cultured for 1 week were assessed and doxSO and doxSA were identified 
as toxic species that accumulate in transgenic cultures but not in wild type 
cultures.  (B) C133W Neurons were treated with hsiRNAs and ASOs at 1.5 
μM concentration. Level of toxic species doxSO and doxSA were quantitated 
at 1 week by mass spectrometry. A trend towards reduction of doxSA by 
hamster-targeting compounds can be seen.  N=6, SD, NTC- Non Targeting 
Control, UNT- Untreated Cells. 
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We then treated primary cortical neurons isolated from transgenic mice for 1 week with 
our lead compounds at a concentration of 1.5 μM.  We found a high degree of variability 
in dSLs among all samples tested, including untreated.  Thus we cannot conclude that 
there is any difference between treatment with hamster-targeting compounds and 
untreated or NTC groups (Fig. 8b).  
 
Discussion  
HSAN1 is a debilitating, autosomal dominantly inherited, neurological disorder resulting 
in a progressive polyneuropathy primarily affecting pain and temperature sensation in the 
distal limbs (Penno, Reilly et al. 2010).  Complications such as amputation and skin and 
bone infections considerably impact patients’ quality of life (Auer-Grumbach 2008).  
Thus far, there are no FDA-approved treatments for this disease (Eichler 2018).  A Phase 
II clinical trial is underway investigating the impact of oral L-serine supplementation on 
disease progression and reversibility of symptoms (Eichler 2017).  As a monogenic 
disorder in which the mutants have a well-described acquired toxic property (production 
of dSLs), HSAN1 is a prime candidate for RNAi-based gene silencing strategies.  In that 
vein, we selected two classes of compounds that have enjoyed recent success in clinical 
development, siRNAs and ASOs, to investigate their ability to downregulate the 
causative gene in HSAN1, SPTLC1.   
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Screening and Validation of Lead Compounds  
We designed and screened a panel of 39 hsiRNAs and 16 ASOs that target hamster 
SPTLC1, which is overexpressed in the C133W transgenic mouse model.  Our hsiRNA 
screens exhibited hit rates of 25.6% and 15.4%, and the ASO compounds showed a much 
higher hit rate than the hsiRNA screens.  On further characterization of the compounds, 
the ASOs tested showed higher potency in CHO cells, with IC50s in the 100 nM range, 
while the hsiRNAs tested were less potent, with IC50s in the 400 nM range.  In mouse 
primary neurons, however, the hsiRNA chemistry had a higher potency, with 
hsiRNA_1143 exhibiting a lower IC50 relative to ASO_489 and ASO_414.  This 
discrepancy is a result of the fact that hsiRNA-1143 was designed specifically to target 
mouse SPTLC1 whereas ASO_489 had a lower efficacy when tested in CHO-K1 cells 
and ASO_414 was not expected to target mouse SPTLC1 at all since it contains a 
mismatch.  We also established the species-specific nature of the lead compounds, with 
hsiRNA_1138 being hamster-selective and hsiRNA_1143 being mouse-selective.  
ASO_489 as anticipated was able to target both hamster and mouse SPTLC1, while 
ASO_414 was able to target hamster SPTLC1 in CHO cells and unable to potently target 
mouse SPTLC1 in wt mouse primary cortical neurons.   
We then demonstrated species-specificity in an in vitro model of HSAN1, transgenic 
primary cortical neuron cultures, expressing both hamster and mouse SPTLC1.  We 
assessed the differential capacity of our lead compounds to knockdown mRNA, protein, 
and toxic dSLs.   
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mRNA Knockdown Analysis 
With regard to mRNA knockdown analysis, two experiments were excluded from the 
analysis, as they exhibited a marked central plate effect.  The plate effect could arise due 
to loose sealing of branched DNA assay plates, which could result in evaporation from 
the outside wells.  Since these experiments demonstrated a plate effect consisting of a 
marked variation in luminescence in the outside wells as compared to central wells, they 
were excluded from analysis, as is the standard practice in the Khvorova lab.  The three 
experiments indicated were used in the analysis.   
Our data indicate that the lead compounds retained their species-specificity with respect 
to mRNA downregulation as compared to their activity in CHO-K1 cells and wild type 
mouse primary cortical neurons.  hsiRNA_1138, ASO_414, and ASO_489 all silence 
hamster SPTLC1 as expected, while hsiRNA_1143, ASO_414, and ASO_489 all silence 
mouse SPTLC1.  As mentioned, ASO_414 was not designed to target mouse SPTLC1, 
but appeared efficacious in wild type mouse primary cortical neurons.  This effect was 
amplified in transgenic mouse primary cortical neurons.  A possible explanation for this 
situation is that the ASO_414 compound became contaminated by the ASO_489 
compound.  Nevertheless, ASO_414 clearly shows higher potency in silencing hamster 
SPTLC1 as compared to mouse SPTLC1, as the IC50 of ASO_414 for hamster SPTLC1 
is less than 50 nM (beyond the limit of detection for the range of concentrations tested).   
Notably, there is a high degree of variability in the IC50 values between experiments.  
This could be due to the fact that each experiment is conducted on a separate batch of 
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primary neurons, derived from a different pregnant mouse.  Since the wild type females 
are crossed with males that are heterozygous for the transgene, each pregnant mouse will 
have embryos that are heterozygous transgenic and wild type.  Neurons from all embryos 
are used to prepare cortical neuron cultures, so there is a different ratio of transgenic to 
wild type neurons in every culture prepared.  Thus, even though the transgene is 
generally highly expressed, the level of expression may vary between cultures.  
Additionally, the level of wild type mouse SPTLC1 is lower in transgenic neurons than in 
wild type neurons (data not shown).  This may indicate the existence of a negative 
feedback mechanism which regulates the overall abundance of SPTLC1 mRNA, whether 
transgenic or wild type, such that it does not become too high.  Thus there may be a high 
degree of variability of both mouse SPTLC1 and hamster SPTLC1 between these 
transgenic cultures, and this may contribute to the high degree of variability observed in 
IC50 values.  Still, the general observations are well-supported among all experiments 
that hsiRNA_1138, ASO_414, and ASO_489 silence hamster SPTLC1, while 
hsiRNA_1143, ASO_414, and ASO_489 silence mouse SPTLC1.   
Additionally, there appears to be a high degree of variability in some experiments among 
the mRNA levels of untreated cells.  This could be due to differential ratios of transgenic 
to wild type neurons within individual wells of the culture plate if cultures were not 
entirely homogenous when plated.  Thus, we chose to normalize data to the more 
numerous readings from NTC wells instead of normalizing to the few untreated wells.  
This may also complicate interpretation of the results and IC50s of the lead compounds.   
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A more optimal experimental design might entail preparing primary cortical neuron 
cultures from individual embryos and testing compounds in cultures derived from only 
heterozygous transgenic embryos in order to minimize these key sources of variability.  
Another option would be to generate a mouse homozygous for the transgene and cross 
this mouse with a wild type mouse, thus ensuring all resulting embryos are heterozygous.   
 
Protein Knockdown Analysis 
The next step was to investigate whether the species selectivity displayed by our reagents 
with respect to mRNA was preserved with respect to protein.  We found that just as in 
mRNA, hsiRNA_1138, ASO_414, and ASO_489 are able to silence hamster LCB1, 
while hsiRNA_1143, ASO_414, and ASO_489 reduce mouse LCB1.  However, the 
hamster-targeting reagents produce a greater degree of silencing than do the mouse-
targeting reagents.  This difference cannot be explained by efficacy.  Compound 
hsiRNA_1139, which had comparable efficacy to ASO_414 in silencing mRNA in both 
wild type and transgenic primary neuron cultures, is unable to silence wild type mouse 
LCB1 protein to the same extent that ASO_414 can reduce hamster LCB1 protein.  One 
potential explanation for this difference in protein silencing is that there is instability of 
the hamster LCB1 protein.  Previous work has shown that mutant LCB1 protein levels 
are reduced compared to wild type protein in other lines of C133W HSAN1 mice 
developed, such as 8B and 8F, while the mutant mRNA is expressed at a level equal to 
endogenous SPTLC1 mRNA(McCampbell, Truong et al. 2005).  Moreover, our findings 
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indicate that there is a more consistent downregulation of LCB1 protein than SPTLC1 
mRNA.  Another factor influencing interpretation of these data is the high degree of 
variability of mouse LCB1 protein expression in untreated cells.  If less variability of 
mouse LCB1 protein was observed in untreated cells, the silencing capability of 
hsiRNA_1143 may have reached statistical significance, although it would remain less 
effective at silencing mouse LCB1 than the hamster-targeting compounds were at 
targeting hamster LCB1.   
 
dSL Knockdown Analysis 
The robust knockdown observed in mRNA and protein after treatment with our lead 
hamster-targeting compounds did not result in a reduction of dSLs.  One issue is that our 
assay to validate doxSO and doxSA as potential markers to distinguish between 
transgenic cultures and wild type cultures and to determine whether this culture system 
could be used to measure knockdown of dSLs was not conducted under optimal 
conditions.  The wild type neurons were cultured for only seven days, while the 
transgenic neurons were cultured for eleven, due to timing of working with a 
collaborator.  Neurons are non-dividing but highly active cells, and these cells were just 
being established in culture over about a weeks’ time.  Thus it is not unexpected that a 
difference in total protein and sphingolipid content would exist, but it is surprising that 
such a large difference exists in cultures that have a difference in culture length of only 
four days.  The health of the cultures may also impact these values, so theoretically a less 
robust wild type culture could result in lower values.  Additionally, it may take time for 
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dSLs to accumulate in these neuronal preparations, and we do not know for certain if dSL 
levels rise rapidly after day seven.  Thus based on this experiment, we cannot 
conclusively state that this assay distinguishes between wild type and transgenic cultures 
or that it can be used for examining knockdown of dSLs.  However, since doxSO and 
doxSA are abundant in transgenic cultures and undetectable in wild type cultures, it is 
likely that this assay is able to distinguish between the two culture types despite sub-
optimal assay design.   
 
Another potential issue is that the culture conditions used do not allow for accurate 
quantitation of dSLs and so even when knockdown occurs, it cannot accurately be 
detected.  To address this issue, we examined the d7SO-normalized values of doxSA and 
doxSO at two different cell numbers (one is double the other) in transgenic cultures.  For 
appropriate assay linearity, we would expect a two fold increase in doxSA and doxSO for 
a two fold increase in total protein.  We found that both doxSO and doxSA did not quite 
fit these parameters, and additionally that the species exhibited high variability, with 
doxSO demonstrating marked variability at the lower cell number.   
 
These two issues indirectly impact the ability to detect knockdown of dSLs, but there 
were also some concerns directly impacting determination of knockdown of dSLs as 
well.  The main concern is that the total protein concentrations of samples, though 
consistent within each experiment, were highly variable between experiments.  This 
could indicate that the health of the neuronal cultures may have been different between 
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different preparations.  Since there are varying proportions of the transgenic neurons, this 
variability is not entirely unexpected.  In the future, cell viability should be monitored in 
conjunction with silencing.   
  
For these reasons, even though a reduction in dSLs was not observed, it may be that 
knockdown is occurring but assay conditions are prohibiting detection of the knockdown.  
It is possible, however, that our lead hamster-targeting compounds do not silence dSL 
production, or that downregulation of LCB1 protein results in no reduction or very slow 
reduction of dSLs that is not able to be measured in the timecourse evaluated.  The 
turnover rate of dSLs has not been studied systematically but is thought to be slow, as 
clinically dSLs accumulate in tissues and sera of affected individuals (Penno, Reilly et al. 
2010).  dSLs are thought to form lipid droplets in macrophages (Eichler, Hornemann et 
al. 2009).  The low rate of turnover and accumulation are surmised to occur because dSLs 
lack an oxygen atom at the C1 carbon, essentially rendering the molecules resistant to 
further reactions (Eichler, Hornemann et al. 2009).  However, evidence from serine 
supplementation experiments supports the notion that treatment of HSAN1 through 
downregulation of hamster mRNA, and thus dSLs, may result in reversal of symptoms.  
Serine is the normal substrate for wild type SPT and in the disease state, mutant SPT 
accepts serine, alanine, and glycine as substrates (Eichler, Hornemann et al. 2009).  
While mutant SPT is activated more often to form products when it uses alanine and 
glycine as substrates (Gable, Gupta et al. 2010), serine supplementation in mice and 
humans can overcome this competition for SPT and reduce dSL formation (Garofalo, 
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Penno et al. 2011).  Furthermore, dietary supplementation with oral L-serine reduces 
dSLs and alleviates symptoms in mice and humans (Garofalo, Penno et al. 2011)  C133W 
mice fed a 10% L-serine–enriched diet demonstrated a 5-fold decrease of doxSA and 
a 10-fold decrease of doxSO and reached WT dSL levels in 2–4 days (Garofalo, Penno 
et al. 2011).  Similarly, C133Y patients dosed with 400 mg/kg/d of L-serine experienced 
4-fold reduction in dSL levels within a month, reaching lowest levels after six weeks and 
persisting at low levels for the remainder of the ten-week study (Garofalo, Penno et al. 
2011).  One way of measuring turnover in our system is by temporarily blocking 
production of dSLs and examining rate of reduction of dSLs.  dSL production could be 
blocked by an oligonucleotide therapeutic such as those developed here or a small 
molecule inhibitor of SPT.   
 
Conclusions 
We have developed and conducted initial studies laying the basis for further in vivo 
characterization of compounds selectively targeting SPTLC1.  Based on our findings, 
hsiRNA-1138, ASO_414, and ASO_489 show the potential to modulate HSAN1 
symptoms in transgenic animals. This study also provides evidence for primary cortical 
neuron culture as an appropriate in vitro model for assessing potential HSAN1 
therapeutics after further optimization of cultures for dSL detection.  These cultures will 
allow for evaluation of knockdown of mRNA, protein, and dSLs.   
56 
 
Importantly, hsiRNA_1138 and ASO_414 are candidates for clinical development, as 
they target human SPTLC1 in addition to hamster SPTLC1.  There are several challenges 
that stand in the way of the development of these powerful oligonucleotide therapeutics 
for the treatment of HSAN1.  There is much that is not yet known about the natural 
history of HSAN1.  We do not know the extent of downregulation of SPTLC1 mRNA, 
and thus protein and dSLs that is needed to ameliorate the HSAN1 phenotype.  We do 
know that mice heterozygous for deletion of SPTLC1 show no phenotype (Gable, Gupta 
et al. 2010), but homozygous knockouts display embryonic lethality (Hojjati, Li et al. 
2005).  There are no known C133W conditional knockout mice to assess whether 
SPTLC1 is only necessary during development or whether a low level of SPTLC1 is 
required even in adulthood of these animals.  In any case, we need to determine the 
optimal level of silencing that alleviates symptoms but does not have negative effects due 
to lack of gene expression.  Our protein knockdown findings support the notion that 
mutant LCB1 protein is relatively unstable, which could complicate development of a 
therapeutic strategy.   
 
While there may be many complicating factors involved in the development and 
treatment of HSAN1 that are even yet to be discovered, further study of this disease is an 
important endeavor.  There are many parallels between patients with HSAN1 and patients 
with Diabetes Mellitus, such as the buildup of toxic dSL species (Dohrn, Othman et al. 
2015, Othman, Saely et al. 2015) in sera and tissues and the development of progressive 
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stocking-glove neuropathies affecting distal limbs.  Investigation into reducing dSLs may 
benefit the myriad DM patients suffering from intractable diabetic neuropathy.   
 
Next steps toward clinical development of these reagents involve optimizing primary 
neuron culture conditions to robustly quantitate dSL levels and investigating whether 
treatment with these reagents reduces dSL levels.  Reduction of dSLs would indicate the 
ability of these reagents to modify a biochemical phenotypic trait of HSAN1.  In vivo 
testing also needs to be conducted.  First, biodistribution to the target tissue, DRG, and 
cell type, large sensory neurons, should be demonstrated.  Then, confirmation of 
silencing efficacy in DRG, as well as pharmacokinetic and pharmacodynamic 
experimentation especially the investigation of duration of silencing should be 
undertaken.  We know that long-term silencing of genes in other tissues, such as brain, 
with similar reagents is possible.  Exploration of silencing of mutant hamster SPTLC1 vs 
silencing of wild type mouse SPTLC1 can elucidate the degree to which mutant SPTLC1 
or both mutant and WT SPTLC1 can be silenced without adverse effects.   
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Appendix  
Introduction:  
HSAN1 affects the dorsal root ganglia (DRG) of patients (McCampbell, Truong et al. 
2005).  This results in loss of DRG cell bodies and denervation, as well as development 
of an axonal neuropathy leading to stocking-glove loss of pain and temperature sensation 
(Garofalo, Penno et al. 2011).  We previously showed that our reagents are able to silence 
hamster and/or mouse SPTLC1 in in vitro systems such as the CHO-K1 cell line, mouse 
primary cortical neuron cultures, as well as transgenic mouse primary cortical neurons 
cultures derived from C133W mice (Karnam 2018).  The next step in the pipeline 
towards clinical drug development is ascertaining the ability to target the appropriate 
tissue type as well as the ability to silence the gene of interest in the tissue type of 
interest.   
HSAN1 affects the sensory neurons of the DRG and primarily involves the lower limbs 
(Eichler, Hornemann et al. 2009).  Several subpopulations of sensory neurons exist 
(McCampbell, Truong et al. 2005).  Within these, the small sensory neurons that are 
TrkA positive and those that are IB4 positive join Aδ and C fibers, which govern pain 
and temperature sensation (McCampbell, Truong et al. 2005).  Thus this is our primary 
therapeutic target.  Mice have 31 pairs of DRG, situated along the spinal cord, housed by 
the spinal column (Sleigh, Weir et al. 2016).  This anatomy facilitates drug delivery to the 
DRG by intrathecal injection.  Chemical modifications of oligonucleotide-based 
therapeutics are known to determine tissue specificity (Hassler, Turanov et al. 2018).  
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Thus we set out to determine and characterize the ability of various chemically modified 
oligonucleotide scaffolds to penetrate the DRG.   
 
Methods:  
WT mice were injected by lumbar intrathecal injection with varying doses of CY3-
conjugated oligonucleotide scaffolds dissolved in PBS (Fig. A1).  After a specified time, 
animals were euthanized by isoflurane overdose and transcardially perfused with PBS.  
Spinal columns were dissected out and either immediately post-fixed in 4% PFA or 10% 
formalin for 24 hours, or DRG and sometimes spinal cord were dissected out and post-
fixed before being stored in PBS.  Brains and livers of treated animals were also 
processed in some experiments.  DRGs and other organs were processed, sectioned, 
mounted, and DAPI stained using standard protocols for histological imaging.  CY3 
(excitation filter 546 nm, emission filter 590 nm) and DAPI (excitation filter 350 nm, 
emission filter 460 nm) were imaged using a Leica DM5500 fluorescent microscope.  
Based on imaging, several parameters were investigated.  Degree of variability refers to 
how variable uptake is among DRGs within the same animal.  Gradient of localization 
from site of injection was examined in some experiments as well.  In these experiments, 
DRGs from along the length of the spinal cord were collected and divided into three 
groups, close to the site of injection (lumbar region), far from the site of injection 
(cervical region), and mid-range (thoracic region).  The degree of localization of 
oligonucleotide scaffolds in these various groups was compared across groups.  Uptake 
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by sensory neurons, satellite cells or other cells, and nerve fibers was also assessed by 
inspection.  Large sensory neurons are easily identified by their distinctly large cell 
bodies and nuclei, while satellite cells are smaller, with denser nuclei (Fig. A2).   
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Figure A1. Structures of hsiRNA scaffolds and conjugates used in 
biodistribution studies 
A. Various hsiRNA scaffolds were tagged with Cy3 or FYE (not shown).  
The P1 and P2 scaffolds were conjugated to either cholesterol (P1) or one 
of several hydrophobic conjugates shown in B (P2).  The P2 dibranched 
structure shows two P2-Cy3 labelled hsiRNAs conjugated by tetraethylene 
glycol.   
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Figure A2. Dorsal Root Ganglion cellular structure 
Hematoxylin-Eosin stained cross section of dorsal root ganglion shows the 
neuron cell bodies (ncb), satellite cells (sc), myelinated axons (ma), and 
dorsal root (dr).  Localization experiments were performed by intrathecal 
injection of CY-3 labelled chemically modified oligonucleotide scaffolds, 
tissue processing and fluorescent microscopy of DRG.  Localization to 
DRG tissue and to cell types was examined.   
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Results:  
Results of the biodistribution studies are summarized in Table A1.  Notably, there is 
marked variation in almost every parameter for most compounds tested.  We are able to 
draw a few broad generalizations, however.  For example, the LNA Gapmer seems to 
target the sensory neurons, as indicated by ++/+++ values in all the experiments 
involving this compound.  In contrast, P1-cholesterol hsiRNA appears to be taken up by 
satellite cells and nerve fibers.  P2-cholesterol hsiRNA appears to show an even greater 
predilection for nerve fibers, with all values ++/+++ for all experiments using this 
compound.  P2-DHA hsiRNA demonstrates marked accumulation in satellite cells.   The 
P2-cholecalciferol compound and the P2-dibranched compound distribute to sensory 
neurons, but at a lower level, ++ as compared to other compounds.  OM1 and OM2 
compounds appear to have promise for targeting sensory neurons as well as satellite cells.   
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Table A1. Results of Biodistribution Experiments 
Compound Experi-
ment ID 
Dose 
(nmol) 
Time 
(hours) 
Degree of 
Variability 
Gradient 
from Site 
of 
Injection 
Sensory 
Neuron 
Distribution 
Satellite 
Cell 
Distribution 
Nerve Fiber 
Distribution 
LNA GapmeR 
 
150304 
 
6 24 Low  N/A ++ ++ +++ 
 150307 
 
6 24 High - +++ - ++ 
 160301 
 
6 24 High +++ ++ ++ + 
P1-chol 
hsiRNA 
 
150304 
 
6 24 Low N/A + +++ ++ 
 150307 
 
6 24 High - + + +++ 
 150401 
 
6 24 0 N/A + ++ - 
 150503 
 
6 24 Medium +++ ++ ++ ++ 
P2-chol 
hsiRNA  
 
150304 
 
6 24 High +++ + - +++ 
  150307 
 
6 24 0 - ++ + ++ 
 150503 
 
6 24 Medium ++ +++ + +++ 
 151116 
 
6 24 N/A N/A + - ++ 
 160301 
 
6 24 High  +++ ++ ++ +++ 
P2-GM1 
hsiRNA 
 
150415 
 
10 48 N/A N/A - - - 
P2-DHA 
hsiRNA 
 
150401 
 
6 24 N/A - ++ +++ + 
 150415 
 
10 48 N/A N/A + +++ - 
 150503 
 
6 24 0 - ++ +++ ++ 
P2-
cholecalciferol 
hsiRNA 
 
150415 
 
10 48 N/A N/A ++ + - 
 150604 
 
6 24 High ++ ++ - + 
 151116 
 
6 24 High  N/A + - - 
P2-cortisol 
hsiRNA 
 
150415 
 
10 48 N/A N/A + +++ - 
OM1-hsiRNA 
 
150618 
 
10 48 0 N/A +++ +++ + 
OM2-hsiRNA 
 
150618 
 
10 48 0 N/A ++ +++ - 
P2-Di 
branched 
hsiRNA 
 
151116 
 
6 24 N/A N/A ++ - ++ 
 160301 
 
6 24 Low + + +++ - 
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Table A1.  
Degree of Variability – how variable is uptake among DRGs within the same animal?  
 0 – no variability appreciable  
 Low – low degree of variability among DRGs examined  
 Medium – there is some difference among DRGs as to how much oligonucleotide  
they take up 
 High – some DRG take up the oligonucleotide to a high degree, whereas others do  
not take up the oligonucleotide at all 
 N/A – Not Assessed  
Gradient from Site of Distribution – how far from the site of injection did the 
oligonucleotide distribute?  
 - – no gradient appreciable 
+ – not much change in distribution across the length of the spinal cord 
 ++ – moderate change in distribution across the length of the spinal cord 
 +++ – high degree of change in distribution across the length of the spinal cord 
 N/A – Not Assessed (i.e. only DRGs from the same general area with respect to 
the spinal cord were examined, whether lumbar, thoracic, or cervical) 
Sensory Neuron/Satellite Cell/Nerve Fiber Distribution – how intense is the CY3 
localization?   
 - – No visible distribution 
+ – low level of distribution, dim  
 ++ – moderate level of distribution 
 +++ – high level of distribution, very bright 
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Discussion:  
The high level of variability in almost all parameters evaluated obscures definitive 
interpretation of the data.  This is exacerbated by the fact that some compounds only had 
one or two experiments investigating their biodistribution.  Furthermore, it is difficult to 
draw conclusions because the experiments were not uniform, and variables such as dose 
as well as timecourse were altered in some cases and so results are not directly 
comparable.  However, even among the experiments with the standardized variables of 6 
nanomole dose and 24 hour timepoint, there still is a lot of variability.  A contributing 
factor is that some experiments had only one animal in the experiment per group, but this 
is less of a concern since in most cases several DRGs were assessed per animal, or in 
many cases, per spinal cord region.    
Perhaps the most defining issue is that after these DRGs were dissected out, they were 
processed by the histology core.  Thus these samples may have been exposed to light for 
varying lengths of time, which may impact the variability observed between experiments 
as well as reduce the amount of oligonucleotide observed in tissue.  Localization of other, 
similar chemical scaffolds to DRG has been investigated in the Khvorova lab by 
removing, demineralizing, and sectioning the whole spinal column.  These investigations 
show robust and more consistent delivery of these oligonucleotides to the DRG (data not 
shown).  Thus these oligonucleotides may represent better chemical configuration to 
target the DRG, or the tissue processing method is one which better preserves signal from 
the CY3-labelled compounds.  DRG biodistribution of a single compound should be 
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assessed, comparing the two tissue processing methods, to determine whether the 
processing method is a factor affecting ability to detect localization to DRG.   
Another potential factor is the fact that in many experiments, a gradient of cellular uptake 
was observed, whereby there was a greater degree of uptake of oligonucleotides closer to 
the injection site as compared to further away from the injection site.  This could be the 
result of high viscosity of the hydrophobic oligonucleotides, which may not migrate or 
disperse efficiently.  In the future, this issue could be addressed by diluting the 
compounds to a lower concentration and injecting a larger bolus or pump infusion of the 
compounds.  Additionally, more animals per group should be used in each study.  
Another factor that could be contributing to variability is the fact that different sequences 
were used for localization experiments.  It is known that chemical modifications 
contribute to tissue specificity (Hassler, Turanov et al. 2018), and previous 
experimentation from the Khvorova lab indicates that sequence differences do not 
contribute to localization patterns.  Once these factors have been optimized, DRG 
localization should be examined in closer detail with markers identifying and 
distinguishing different populations of cells.   
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